GB
Girish Bhimrao Jaiwal
About Girish Bhimrao Jaiwal
Data last updated:
Girish Bhimrao Jaiwal is a Director at Kings Global Biotech Limited (since 2016) and Director at Skp Global Medicines Private Limited (since 2016). The companies operate in Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹61.00 Cr; the largest is Kings Global Biotech Limited at ₹50.04 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Kings Global Biotech Limited U33119PN2016PLC164905 | Director | 09 Jun 2016 | 2016 | ₹50.04 Cr (FY 2024) | Active |
 Skp Global Medicines Private Limited U33100PN2016PTC166968 | Director | 28 Oct 2016 | 2016 | ₹10.96 Cr (FY 2024) | Active |
Board colleagues of Girish Bhimrao Jaiwal
| Name | DIN | Company | Designation |
|---|---|---|---|
| Kartiki Ramesh Tupe | 09165268 | Kings Global Biotech Limited | Additional Director |
| Manodnya Shashank Sapre | 08157053 | Kings Global Biotech Limited , Skp Global Medicines Private Limited | Whole-Time Director |
| Ramesh Murlidhar Tupe | 09166739 | Skp Global Medicines Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Girish Bhimrao Jaiwal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Girish Bhimrao Jaiwal
Girish Bhimrao Jaiwal currently holds 2 directorships: Kings Global Biotech Limited (Director, since 09 Jun 2016, revenue ₹50.04 Cr (FY 2024)); Skp Global Medicines Private Limited (Director, since 28 Oct 2016, revenue ₹10.96 Cr (FY 2024)).
Girish Bhimrao Jaiwal was first appointed on 09 Jun 2016 as Director at Kings Global Biotech Limited.
The 2 current companies of Girish Bhimrao Jaiwal that report revenue have a combined latest revenue of ₹61.00 Cr: Kings Global Biotech Limited ₹50.04 Cr (FY 2024); Skp Global Medicines Private Limited ₹10.96 Cr (FY 2024).
The current boards of Girish Bhimrao Jaiwal's companies include Kartiki Ramesh Tupe (Kings Global Biotech Limited), Manodnya Shashank Sapre (Kings Global Biotech Limited), Ramesh Murlidhar Tupe (Skp Global Medicines Private Limited).